Company intelligence / Profile preview
NeuroSense Therapeutics
Herzliya, Israelneurosense-tx.com ↗
- Ownership
- Public · NRSN
- Employees
- ~17
- Development stage
- Other
01
Overview
Phase 2b PARADIGM trial showed PrimeC reduced ALS disease progression by 33-36% and improved survival rates by 43-58%. Complication-free survival showed 57-73% difference favoring PrimeC over placebo after 12 months.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesFixed-dose combination drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
In discussions with a global pharmaceutical company as of April 2025
04
Financials
- Market cap
- $2.6M
- Total revenue
- $0
- Enterprise value
- $2.4M
Beyond the preview
Go deeper on NeuroSense Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroSense Therapeutics.